[PDF][PDF] Multifactorial approach to predicting resistance to anthracyclines

C Desmedt, A Di Leo, E De Azambuja, D Larsimont… - J Clin Oncol, 2011 - academia.edu
C Desmedt, A Di Leo, E De Azambuja, D Larsimont, B Haibe-Kains, J Selleslags…
J Clin Oncol, 2011academia.edu
Purpose Validated biomarkers predictive of response/resistance to anthracyclines in breast
cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which
patients with estrogen receptor (ER)–negative tumors were treated with anthracycline
(epirubicin) monotherapy, was specifically designed to evaluate the predictive value of
topoisomerase II-(TOP2A) and develop a gene expression signature to identify those
patients who do not benefit from anthracyclines.
Purpose
Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)–negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-(TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines.
academia.edu